1 |
ClinicalTrials.gov (NCT02061761) Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM. U.S. National Institutes of Health.
|
2 |
Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
|
3 |
FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
|
4 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
5 |
A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
|
6 |
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
|
7 |
Clinical pipeline report, company report or official report of Xencor.
|
8 |
Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
|
9 |
Clinical pipeline report, company report or official report of Genentech.
|
10 |
Clinical pipeline report, company report or official report of Novartis.
|
11 |
IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
|
12 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
|
|
|
|
|
|